Lithium Ion

Lithium Ion

SCHEMBL3590770

O=C([O-])c1ccc(OCc2cscn2)cc1F.[Li+]

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.42
PKM P14618 1/20 0.42
MET P08581 1/20 0.41
MAOA P21397 1/20 0.41
PARP10 Q53GL7 4/20 0.39
PARP15 Q460N3 2/20 0.39
PARP14 Q460N5 1/20 0.38
NOX1 Q9Y5S8 1/20 0.38
ALOX5 P09917 2/20 0.37
PPARG P37231 2/20 0.36
PPARA Q07869 2/20 0.36
ACHE P22303 1/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ALOX5AP P20292 1/20 0.35
MAPK14 Q16539 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3590769 0.86 MAOB (0.46) MAOBPKMMETMAOAPARP10
SCHEMBL3583451 0.84 MAOB (0.44) MAOBPKMMETMAOAPARP10
Lithium Ion SCHEMBL3274392 0.79 PARP10 (0.51) MAOBMETPARP10PARP15PARP14
SCHEMBL29468840 0.76 IDO1 (0.39) MAOBALOX5ACHEALOX5AP
SCHEMBL24302655 0.74 ALDH1A1 (0.40) MAOBPKMPARP10PARP15ALOX5
SCHEMBL4660944 0.72 MET (0.40) MAOBMETMAOAALOX5TDP1
SCHEMBL3578478 0.72 MET (0.45) MET
SCHEMBL16621263 0.70 NR4A2 (0.53) PKMALOX5
SCHEMBL8799334 0.68 ALOX5 (0.46) MAOBPKMMETMAOAPARP10
SCHEMBL27950179 0.66 L3MBTL1 (0.44) MEN1MAPTKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846950-B2 Histamine H3 receptor inhibitors, preparation and therapeutic uses ELI LILLY AND COMPANY (US) 2010-12-07 US disclosed
EP-1805169-B1 HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES LILLY CO ELI (US) 2008-12-24 EP disclosed
US-20080015235-A1 Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses JESUDASON CYNTHIA D 2008-01-17 US disclosed
EP-1805169-A1 HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES Eli Lilly and Company (US) 2007-07-11 EP disclosed
WO-2006044228-A1 HISTAMINE H3 RECEPTOR INHIBITORS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015235-A1 Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses HRH3, HRH4, HCRTR1 MAOB 618/4885PKM 2789/4885MET 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.